Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study

Hsiu Li Lin, Hsiu Chen Lin, Yuan Fu Tseng, Shih Chang Chen, Chien Yeh Hsu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: This retrospective cohort study used a population-based dataset to test the risk for parkinsonism in patients receiving flunarizine and cinnarizine, compared with matched controls. Methods: Data were obtained from the National Health Insurance Research Dataset of Taiwan. Patients receiving flunarizine or cinnarizine for more than 1 month between 2000 and 2005 were enrolled. Exclusion criteria included receiving flunarizine, cinnarizine, or antipsychotics for more than 1 month during 1997–1999, a history of neurodegenerative diseases, and an age of less than 30 years. One matched control for each patient was selected. Each participant was followed for diagnosis of parkinsonism within a 3-year observation period. Stroke, diabetes mellitus, total prescription days, and doses of flunarizine or cinnarizine were recorded. Results: The study and control groups consisted of 9830 subjects. In the study group, 280 patients (2.9 %) were diagnosed with parkinsonism with a median observation period of 1.2 years, and 49 participants (0.5 %) were diagnosed in the control group with a median observation period of 1.9 years. The adjusted hazard ratio for parkinsonism among patients receiving flunarizine and cinnarizine was 5.117 (95 % CI = 3.758–6.967). Age, stroke, and diabetes mellitus were significant risk factors, but female sex and total doses of the study drugs were not. Conclusions: This study demonstrates that flunarizine and cinnarizine significantly increase the risk for parkinsonism. The treatment benefits of these two agents should be balanced with this adverse effect. Physicians must look carefully for early signs of parkinsonism in patients treated with flunarizine and cinnarizine.

Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume73
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Cinnarizine
Flunarizine
Parkinsonian Disorders
Population
Observation
Diabetes Mellitus
Stroke
Control Groups
National Health Programs
Taiwan
Neurodegenerative Diseases
Antipsychotic Agents
Prescriptions
Cohort Studies
Retrospective Studies
Physicians

Keywords

  • Cinnarizine
  • Drug-induced parkinsonism
  • Flunarizine
  • Health insurance research dataset
  • Parkinsonism

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Risk of parkinsonism induced by flunarizine or cinnarizine : a population-based study. / Lin, Hsiu Li; Lin, Hsiu Chen; Tseng, Yuan Fu; Chen, Shih Chang; Hsu, Chien Yeh.

In: European Journal of Clinical Pharmacology, Vol. 73, No. 3, 01.03.2017, p. 365-371.

Research output: Contribution to journalArticle

Lin, Hsiu Li ; Lin, Hsiu Chen ; Tseng, Yuan Fu ; Chen, Shih Chang ; Hsu, Chien Yeh. / Risk of parkinsonism induced by flunarizine or cinnarizine : a population-based study. In: European Journal of Clinical Pharmacology. 2017 ; Vol. 73, No. 3. pp. 365-371.
@article{51292a1a6300460c8c05c751b49617f0,
title = "Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study",
abstract = "Purpose: This retrospective cohort study used a population-based dataset to test the risk for parkinsonism in patients receiving flunarizine and cinnarizine, compared with matched controls. Methods: Data were obtained from the National Health Insurance Research Dataset of Taiwan. Patients receiving flunarizine or cinnarizine for more than 1 month between 2000 and 2005 were enrolled. Exclusion criteria included receiving flunarizine, cinnarizine, or antipsychotics for more than 1 month during 1997–1999, a history of neurodegenerative diseases, and an age of less than 30 years. One matched control for each patient was selected. Each participant was followed for diagnosis of parkinsonism within a 3-year observation period. Stroke, diabetes mellitus, total prescription days, and doses of flunarizine or cinnarizine were recorded. Results: The study and control groups consisted of 9830 subjects. In the study group, 280 patients (2.9 {\%}) were diagnosed with parkinsonism with a median observation period of 1.2 years, and 49 participants (0.5 {\%}) were diagnosed in the control group with a median observation period of 1.9 years. The adjusted hazard ratio for parkinsonism among patients receiving flunarizine and cinnarizine was 5.117 (95 {\%} CI = 3.758–6.967). Age, stroke, and diabetes mellitus were significant risk factors, but female sex and total doses of the study drugs were not. Conclusions: This study demonstrates that flunarizine and cinnarizine significantly increase the risk for parkinsonism. The treatment benefits of these two agents should be balanced with this adverse effect. Physicians must look carefully for early signs of parkinsonism in patients treated with flunarizine and cinnarizine.",
keywords = "Cinnarizine, Drug-induced parkinsonism, Flunarizine, Health insurance research dataset, Parkinsonism",
author = "Lin, {Hsiu Li} and Lin, {Hsiu Chen} and Tseng, {Yuan Fu} and Chen, {Shih Chang} and Hsu, {Chien Yeh}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00228-016-2181-3",
language = "English",
volume = "73",
pages = "365--371",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Risk of parkinsonism induced by flunarizine or cinnarizine

T2 - a population-based study

AU - Lin, Hsiu Li

AU - Lin, Hsiu Chen

AU - Tseng, Yuan Fu

AU - Chen, Shih Chang

AU - Hsu, Chien Yeh

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: This retrospective cohort study used a population-based dataset to test the risk for parkinsonism in patients receiving flunarizine and cinnarizine, compared with matched controls. Methods: Data were obtained from the National Health Insurance Research Dataset of Taiwan. Patients receiving flunarizine or cinnarizine for more than 1 month between 2000 and 2005 were enrolled. Exclusion criteria included receiving flunarizine, cinnarizine, or antipsychotics for more than 1 month during 1997–1999, a history of neurodegenerative diseases, and an age of less than 30 years. One matched control for each patient was selected. Each participant was followed for diagnosis of parkinsonism within a 3-year observation period. Stroke, diabetes mellitus, total prescription days, and doses of flunarizine or cinnarizine were recorded. Results: The study and control groups consisted of 9830 subjects. In the study group, 280 patients (2.9 %) were diagnosed with parkinsonism with a median observation period of 1.2 years, and 49 participants (0.5 %) were diagnosed in the control group with a median observation period of 1.9 years. The adjusted hazard ratio for parkinsonism among patients receiving flunarizine and cinnarizine was 5.117 (95 % CI = 3.758–6.967). Age, stroke, and diabetes mellitus were significant risk factors, but female sex and total doses of the study drugs were not. Conclusions: This study demonstrates that flunarizine and cinnarizine significantly increase the risk for parkinsonism. The treatment benefits of these two agents should be balanced with this adverse effect. Physicians must look carefully for early signs of parkinsonism in patients treated with flunarizine and cinnarizine.

AB - Purpose: This retrospective cohort study used a population-based dataset to test the risk for parkinsonism in patients receiving flunarizine and cinnarizine, compared with matched controls. Methods: Data were obtained from the National Health Insurance Research Dataset of Taiwan. Patients receiving flunarizine or cinnarizine for more than 1 month between 2000 and 2005 were enrolled. Exclusion criteria included receiving flunarizine, cinnarizine, or antipsychotics for more than 1 month during 1997–1999, a history of neurodegenerative diseases, and an age of less than 30 years. One matched control for each patient was selected. Each participant was followed for diagnosis of parkinsonism within a 3-year observation period. Stroke, diabetes mellitus, total prescription days, and doses of flunarizine or cinnarizine were recorded. Results: The study and control groups consisted of 9830 subjects. In the study group, 280 patients (2.9 %) were diagnosed with parkinsonism with a median observation period of 1.2 years, and 49 participants (0.5 %) were diagnosed in the control group with a median observation period of 1.9 years. The adjusted hazard ratio for parkinsonism among patients receiving flunarizine and cinnarizine was 5.117 (95 % CI = 3.758–6.967). Age, stroke, and diabetes mellitus were significant risk factors, but female sex and total doses of the study drugs were not. Conclusions: This study demonstrates that flunarizine and cinnarizine significantly increase the risk for parkinsonism. The treatment benefits of these two agents should be balanced with this adverse effect. Physicians must look carefully for early signs of parkinsonism in patients treated with flunarizine and cinnarizine.

KW - Cinnarizine

KW - Drug-induced parkinsonism

KW - Flunarizine

KW - Health insurance research dataset

KW - Parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=85006364841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006364841&partnerID=8YFLogxK

U2 - 10.1007/s00228-016-2181-3

DO - 10.1007/s00228-016-2181-3

M3 - Article

C2 - 27986997

AN - SCOPUS:85006364841

VL - 73

SP - 365

EP - 371

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 3

ER -